
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc. has demonstrated significant clinical efficacy in its pipeline, particularly with icotrokinra, which shows progressive improvement in clinical response and endoscopic outcomes over time, indicating strong potential for successful treatment outcomes. The company's approach to targeting inflammatory diseases and leveraging its proprietary technology platform positions it strategically for growth, especially in the absence of effective competitors like Otezla. Furthermore, the strong business development track record of Protagonist and upcoming key catalysts projected for 2025 suggest a robust trajectory for the company, signaling a positive outlook on its future performance.
Bears say
Protagonist Therapeutics Inc faces significant challenges in its clinical development and competitive landscape, particularly with icotrokinra, despite its standout efficacy profile compared to existing oral treatment options for psoriasis. The company is exposed to various risks, including potential safety concerns from ongoing clinical trials, the possibility that strategic partners may withdraw from development due to competitive dynamics, and the implications of regulatory changes affecting pricing in the market. Additionally, concerns regarding future cash needs and the threat of dilution further contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares